ABSTRACT
The seeding and working banks of a 4647-cell culture have been created. The 4647-cell culture in these banks has a high proliferative activity, as well as the morphology, typical of this line, and the karyotype and the enzymogram, which are characteristic for the cells of an African talapoin (Cercopithecus aethiops). The culture is not contaminated with bacteria, fungi, Mycoplasma, and viruses, including oncoviruses. The deposited 4647 cells have high viral productive properties for the accumulation of the recombinant virus strain b7,5S2-S vaccine and keep the stability of all biological properties during a long-term cultivation. The continuous 4647 cell line was tested at the L. A. Tarasevich State Institute of SK. The seeding and working banks of 4647-cell culture at passages 108 and 128 are recommended as a substrate for cultivation of the strain b7,5S2-S vaccinia, used to prepare a bivaccine against smallpox and hepatitis B.
Subject(s)
Cell Line/physiology , Hepatitis B Vaccines/standards , Industrial Microbiology/standards , Smallpox Vaccine/standards , Animals , Cell Line/microbiology , Chlorocebus aethiops , Hepacivirus/growth & development , Hepatitis B/immunology , Karyotyping , Poxviridae/growth & development , Reference Standards , Smallpox/immunology , Vaccines, Synthetic , Virus Cultivation/standardsABSTRACT
The anticancer drug Cancerolysin has been developed, by using the mutant Adel2 variant of human adenovirus serotype 5 designed at the State Research Center of Virology and Biotechnology. Cancerolysin possesses a high degree of replication activity for complementary cells 293 and p53-deficient tumor cells and, at the same time, has significant replication limitations in normal human cells. Preclinical studies of the drug on laboratory animals (mice, rabbits, guinea pigs) have demonstrated its harmlessness and safety. When stored at -40 and -70 degrees C, the drug showed no significant activity throughout the control observational period (1 year).
Subject(s)
Adenoviridae , Antineoplastic Agents , Cytopathogenic Effect, Viral , Oncolytic Virotherapy , Adenoviridae/genetics , Anaphylaxis , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/immunology , Antineoplastic Agents/toxicity , Cell Line, Transformed , Cell Line, Tumor , Guinea Pigs , Humans , Immunosuppression Therapy , Injections, Intraperitoneal , Injections, Subcutaneous , Macrophages, Peritoneal/immunology , Mice , Mice, Inbred BALB C , Phagocytosis , Rabbits , Virus ReplicationABSTRACT
Certification of continuous cell 293 culture used for cultivation of antineoplastic preparation Cancerolysin was carried out. The seeding and working banks of cells 293 were established and deposited for storage at the Vector Centre. The cells were certified in accordance with the WHO requirements. The cell 293 culture was shown to have high proliferative activity; morphology typical of the line; its karyotype and enzymogram are typical of human cells; the culture is not contaminated with bacteria, fungi, mycoplasms and viruses including oncogenic ones; it has high virus-producing activity; it preserves stability of all the biological properties in long-term cultivation. The seeding and working cell banks were recommended for the use in production of drugs for the treatment of oncologic patients.
